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Cardiac development arises from two sources of mesoderm progenitors, the first (FHF) 
and the second heart field (SHF). Mesp1 has been proposed to mark the most primitive 
multipotent cardiac progenitors common for both heart fields. Here, using clonal 
analysis of the earliest prospective cardiovascular progenitors in a temporally controlled 
manner during the early gastrulation, we found that Mesp1 progenitors consist of two 
temporally distinct pools of progenitors restricted to either the FHF or the SHF. FHF 
progenitors were unipotent, while SHF progenitors, were either uni- or bipotent. 
Microarray and single cell RT-PCR analysis of Mesp1 progenitors revealed the existence 
of molecularly distinct populations of Mesp1 progenitors, consistent with their lineage 
and regional contribution. Altogether, these results provide evidence that heart 
development arises from distinct populations of unipotent and bipotent cardiac 
progenitors that independently express Mesp1 at different time points during their 
specification, revealing that the regional segregation and lineage restriction of cardiac 
progenitors occurs very early during gastrulation. 
 
Introduction 
The mammalian heart is the first functional organ that forms during embryonic 
development and is composed of cardiomyocytes (CMs), endothelial cells (ECs), epicardial 
cells (EPDCs), and smooth muscle cells (SMCs) 1. Cardiac development arises from two 
sources of mesoderm progenitors, namely the first heart field (FHF) and the second heart field 
(SHF) 2, 3. Retrospective clonal analysis suggests the existence of a common progenitor for 
both heart fields, although the timing of the lineage segregation between these two 
progenitors remains unclear 3.  Mesp1 is the earliest known marker of cardiac progenitors 4, 5. 
Overexpression of Mesp1 in ESCs 6-9 suggest that Mesp1 promotes the specification of the 
most primitive multipotent cardiac progenitors common for both heart fields 7. Lineage 
tracing using Mesp1-Cre, in which the recombinase Cre has been knocked-in under the 
regulatory region of Mesp1, showed also that almost all myocardial cells, including 
derivatives of the FHF and SHF, derive from Mesp1 expressing progenitors 4. However, 
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lineage tracing using Mesp1-Cre and a single fluorescent reporter protein at the population 
level does not allow the assessment of whether FHF and SHF progenitors arise from a 
common progenitor or whether Mesp1 is expressed independently in distinct cardiac 
progenitors. To identify the developmental origin of organ regionalization and the timing of 
lineage segregation, it is essential to perform temporal clonal labelling in prospective 
progenitors 10.  
One of the key questions in mammalian development is the timing with which the 
progenitor becomes specified to differentiate into their different lineages. During heart 
development, it has been initially proposed using DiI labelling or retroviral transduction of 
the primitive streak of chick embryos that cardiac and vascular lineage could be already pre-
specified at this early stage of gastrulation 11, 12. In contrast, subsequent genetic lineage tracing 
in vivo and clonal differentiation of cardiovascular progenitors in vitro supports the notion 
that, during mouse embryonic development, cardiovascular progenitors remain multipotent 
until the latter stages of cardiogenesis at the time where they begin to express transcription 
factors such as Nkx2-5 and Isl1 6, 7, 13-15. No study has assessed so far, at the early stage of 
gastrulation, the fate of prospective mouse cardiovascular progenitors into the different 
cardiovascular lineages using single cell marking in vivo.  
 
Results 
Dox inducible Mesp1 reporter and CRE mediated recombination  
To assess the contribution of single Mesp1 expressing progenitors at different time 
points during embryonic development, we generated a tetracycline Mesp1-Tet-on inducible 
transgenic mice, in which the doxycycline dependent transactivator (Mesp1-rtTA) is 
expressed under the control of a fragment of the Mesp1 promoter expressed in cardiac 
progenitors during mouse embryonic development and ESC differentiation 6, 16 (Fig. 1). We 
identified 6 Mesp1-rtTA founders that produce embryos with faithful expression of the 
tdTomato in the heart when Dox was administrated to Mesp1-rtTA/tetO-Cre/Rosa-dtTomato 
embryos between E6.25 and E7.5, corresponding to the timing of endogenous Mesp1 
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expression 4, 17. The expression of the tdTomato was similar to that found in the Mesp1-
Cre/Rosa-tdTomato embryos (Fig. 1a and h), indicating that the Mesp1-rtTA transgene targets 
the same cells as in Mesp1-Cre knock-in. Dox administration during the latter stage of cardiac 
development in Mesp1-rtTA/tetO-Cre/Rosa-dtTomato embryos after E8.0 did not induce 
dtTomato expression, consistent with the transient expression of Mesp1 during the early step 
of cardiovascular progenitor specification 4 (Fig. 1h). Finally, Dox administration to Mesp1-
rtTA/tetO-Cre/Rosa-dtTomato embryos leads to the same labelling of all cardiovascular cell 
types of the FHF and SHF such as CMs, conduction cells, endocardial cells, EPDCs (Fig. 1a-
n), with the exception of some unlabelled SMC in the SHF deriving from the neural crest 18 
(Supplementary Fig. S1a-b).  
To assess the temporal activation of the Mesp1-rtTA transgene upon Dox 
administration, we administrated Dox to Mesp1-rtTA/tet-O-H2B-GFP mice at E6.25, at the 
beginning of gastrulation, when Mesp1 begins to be expressed 4, 17. Already at 5 hours 
following Dox administration, H2B-GFP was detectable in the primitive streak (PS) and the 
nascent cardiac mesoderm (Fig. 1o), in a similar pattern to that previously reported for 
Mesp1-LacZ knockin mice 4, 17. Dox administration did not change the level or the localisation 
of Mesp1 (Supplementary Fig S1c-e). Cre and Mesp1 ISH 6h after Dox treatment at E6.25 
revealed that at E6.25 Mesp1 and Cre were expressed at the same localisation in Mesp1-Cre 
knockin and Mesp1-rtTA/tetO-Cre embryos treated with Dox (Supplementary Fig S1f-h). 
PCR analysis showed that the Rosa-dtTomato locus was recombined, as early as 6h following 
Dox administration at E6.25 and E7.25, similar to Mesp1-Cre knockin embryos (Fig. 1p). All 
of these experiments indicate that Dox administration to Mesp1-rtTA/tetO-Cre embryos 
targets cardiovascular progenitors of both heart fields and faithfully recapitulates Mesp1-Cre 
knockin mice.  
 
Two temporally distinct populations of Mesp1 progenitors contribute to the FHF and 
SHF development. 
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To investigate the contribution of single Mesp1 expressing cells, we titrated the dose 
of Dox required to label Mesp1-rtTA/tetO-Cre/Rosa-Confetti hearts at clonal density, as 
defined by the dose of Dox allowing the recombination of a single fluorescent protein per 
heart. No leakiness in Mesp1-rtTA/tetO-Cre/Rosa-Confetti mice was observed. 
Administration of 0.575 µg/g of Dox was the lowest dose that could be used to induce the 
labelling of very few cardiac progenitors from E6.25 to E7.25, and no embryo showed 
fluorescently marked heart cells after 0.575 µg/g of Dox was administrated before E6.25 or 
after E8.5 (Supplementary Fig. S2a).  
To assess whether a single Mesp1 derived cell could contribute to both the FHF and 
SHF and thereby mark a common progenitor of both heart fields, we used this lowest dose of 
Dox administrated between E6.25 and E7.25, and analysed the contribution of labelled clones 
to heart morphogenesis at E12.5 (Fig. 2a and b), when the segregation between the FHF and 
SHF derivatives is clearly established 3, 19. From the ensemble of labelled hearts, 22% (37 out 
of 161) were unicolour, expressing only one of the four fluorescent proteins, possibly arising 
from a single recombination event. However, in these unicolour hearts resulting from very 
low Cre activity, the frequency of different colours were not equal: YFP and RFP were over-
represented as compared to the CFP and nuclear GFP (Fig. 2c), with the latter almost not 
expressed at all, as previously reported 20. Such unicolour-labelled hearts may arise from a 
single or multiple recombination events.  
Unicolour hearts collected at E8.5 contained no more than 12 labelled cells, 
identifiable as a cluster of unicolour labelled cells in the heart tube (Fig. 2d, e), which were 
not always cohesive (Fig. 2e). These data support the idea that Mesp1 derived progenitors 
minimally expand from their specification in the primitive streak to the initial stage of heart 
tube development and may undergo a certain degree of cellular dispersion or fragmentation. 
Interestingly, by E12.5, most of the single colour hearts contained more than one cluster of 
labelled cells with a mean of about 3 clusters per heart (2.5 clusters +/- 0.37) suggesting that, 
during heart expansion, clones derived from Mesp1 derived progenitors may become 
separated into more than one fragment (Fig. 2f, g), so that the total number of labelled patches 
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represents the combined result of multiple cell induction and clonal fragmentation (see 
Supplementary Theory).  
To functionally categorize with high fidelity the relative contribution of Mesp1 
expressing cells to the FHF and SHF lineages, we defined as FHF derivatives embryos in 
which left ventricle (LV) was labelled, and SHF derivatives hearts in which the outflow tract 
(OFT) and inflow tract (IFT) were labelled 3, 21. Out of 27 unicolour hearts analyzed at E12.5, 
all labelled cells were restricted to either the FHF or SHF derivatives, but no unicolour clones 
were found to be present in both heart fields (Fig. 2f-k). Only 2 out of 27 unicolour hearts 
could not be classified into FHF or SHF, as they presented clones located only in the atria or 
the right ventricle, which are believed to derive from both heart fields 3, 19 (Fig. 2k).  
Since clonal dose of Dox did not induce heart labelling when administrated at E5.75 
(Supplementary Fig. S2), we administrated a dose of Dox 40X higher to investigate whether 
Dox administration before E6.25 can target early multipotent Mesp1 expressing cells that 
would escape our clonal analysis. This early induction marked cells that were exclusively 
distributed in the FHF and never in both FHF and SHF (Supplementary Fig. S2), consistent 
with the results obtained by clonal analysis at E6.25, and ruling out the possibility that early 
Mesp1 expressing cells common for both heart fields were missed in our clonal tracing.  
As all unicolour Mesp1 labelled progenitors appear to be already restricted to the 
FHF and SHF, we then investigated whether these two distinct pools of cardiac progenitors 
are specified at different time points during heart development.  To address this question, we 
categorized the regional contribution of Mesp1 labelled cells (FHF and SHF) according to the 
time of Dox administration to induce the labelling of Mesp1 cardiac progenitors (Fig. 2h-k). 
Dox administration at the earliest time point of cardiac progenitor specification resulted in the 
preferential labelling of the LV  (6 out of 7 hearts at E6.25 and 6 out of 7 hearts at E6.75) 
(Fig. 2h, i, k, l), consistent with the initial emergence of Mesp1 derived FHF progenitors. In 
contrast, Dox administration at a later time point (E7.25) induced a preferential labelling of 
SHF derivatives (10 out of 13 hearts) (Fig. 2j-l).  
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Bio-statistical modeling of the multicolour labelled hearts to infer clonal fragmentation 
and multiregional contribution of single Mesp1 expressing cells. 
Although this observation strongly suggests that Mesp1 progenitors are already 
restricted to the FHF or SHF, to define the degree of clonal fragmentation, the regional 
contribution of the distinct progenitor pools, and the timing of their specification, we turned 
to a more rigorous statistical analysis based on the full range of clonal data including 
multicolour hearts expressing more than one fluorescent protein (Fig. 3a-b). Although cell 
labelling and clonal fragmentation occur in a stochastic manner (Fig. 3c), the relative 
induction frequency, pN (defined as the probability of induction of an individual Mesp1 
expressing cell times the total number of cardiac precursors), and the clonal fragmentation 
rate, f, could be inferred from the total ensemble of labelled hearts (161 labelled hearts 
translating to n=263 independent hearts by colour) using statistical inference (Fig. 3d and 
Supplementary Theory). By comparing the relative frequency of bicolour and tricolour hearts, 
we could infer the induction frequency, 𝑝𝑁 = 1.3 1±0.05, independent of the clone 
fragmentation rate. Then, by fitting the distribution of fragment numbers to a model based on 
stochastic fragmentation (Fig. 3e and Supplementary Fig. S3a, b), we found a fragmentation 
rate of 𝑓 = 1.6 ± 0.2.  
With the known fragmentation rate 𝑓 and induction frequency 𝑝𝑁, we could then 
assess with a defined level of confidence which of the labelled hearts of any given colour are 
likely to derive from a single induced cell. In particular, we found that hearts with 3 
fragments or less of a given colour were likely to be monoclonal (Fig. 3f, examples in Fig. 
3g-h, Supplementary Table S1 and Theory). Following this classification, we identified 89 
clones in our collection of multicolour hearts that were likely to be of monoclonal origin. 
Remarkably, we found that all of the clones that contained fragments in the FHF or SHF were 
restricted to one or the other heart field. None of these clones contributed to both heart fields, 
confirming that the FHF and SHF progenitors arise from distinct Mesp1 progenitors. By 
contrast, of the 69 clones that had fragments in the FHF, 15% also have fragments in the other 
heart compartments. Similarly, of the 20 clones that have fragments in the SHF, 55% have 
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fragments in other heart compartments (Fig. 3i and Supplementary Table S1), demonstrating 
that once heart progenitors have been specified, they are likely to undergo clonal 
fragmentation that will contribute to the morphogenesis of distinct heart regions, consistent 
with the regions associated with the FHF and the SHF obtained by retrospective clonal 
analysis 3.  
By assessing the proportion of FHF and SHF precursors that are labelled at each 
induction time, we found that most FHF derivatives were induced from E6.25 to E6.75 while 
most SHF derivatives were labelled between E6.75 and E7.25 (Fig. 3j). Finally, by computing 
pN and f for each heart field separately, we found that 𝑓 = 1.4 ± 0.2 for the FHF while 𝑓 = 1.9 ± 0.3  for the SHF showing that the latter undergoes a slightly higher rate of 
fragmentation (Supplementary Fig. S3c). Altogether, these results indicate that Mesp1 
expressing cardiac progenitors consist of two temporally distinct populations that sequentially 
contribute to FHF and SHF development. 
Mesp1 lineage is not exclusive to the heart but also marks other mesodermal lineages 
such as head muscles 22, 23. Retrospective clonal analysis has suggested a common origin for 
the head muscles and myocardium derived from the SHF 24. Interestingly, 11% of the 
embryos anlayzed showed co-labelling of the head muscles and the heart with the same 
colour (Supplementary Fig S4a-b). The labelling of the head muscles was preferentially 
observed at the late induction time (Supplementary Fig. S4c) and was associated with the 
labelling of SHF derivatives including the RV (Supplementary Fig. S4d). These results 
indicate that common progenitors for head muscles and heart myocardium encompass the 
pool of Mesp1 progenitors contributing to the SHF, consistent with previous retrospective 
clonal analysis 24. 
 
Mesp1 progenitors consist of unipotent and bipotent progenitors 
Until now, most studies assessing the differentiation potential of cardiac progenitor 
cells at the clonal level have been performed in vitro, and therefore may lack some important 
extrinsic cues that cardiac progenitors encounter during their in vivo specification. In vitro 
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differentiation of single FACS isolated early cardiac progenitors (Mesp1-GFP or Brachyury-
GFP/Flk1) from mouse embryo and during ESC differentiation, shows that these early cardiac 
progenitors differentiate into CMs, ECs, and SMCs, a fraction of which are multipotent at the 
clonal level 15. Likewise, later born Nkx2-5/cKit positive cardiac progenitors cells, which are 
preferentially enriched for FHF progenitors differentiate into CMs, SMCs or both 13, while 
Isl1/Flk1+ cells, which are preferentially enriched for SHF progenitors, give rise to colonies 
that differentiate into CMs, SMCs and ECs at the clonal level in vitro 14. Conflicting results 
have been obtained concerning the fate of cardiac progenitors in vivo during vertebrate 
development 25. Dye and retroviral based tracing during chick heart morphogenesis suggest 
that CMs and ECs arise from distinct pools of progenitors 11, 12, while lineage tracing in 
mouse embryos using Nkx2-5 and Isl1-Cre showed that these progenitors can differentiate 
into myocardium, smooth muscle, and endothelial cells at the population level 14, 26, 27, 
supporting the notion that during mouse development, cardiac progenitors are multipotent 25. 
However, the constitutive activity of the Cre expressed in the cardiac cells precludes 
assessment at the clonal level as to whether the different cell types (CMs, SMCs, and ECs) 
arise from multipotent or distinct unipotent progenitors.  
To assess the fate of single Mesp1 expressing progenitors during cardiovascular 
development in vivo, we assessed the co-expression of fluorescent proteins with specific 
markers of the different cardiovascular cell types in clonally induced Mesp1-rtTA/tetO-
Cre/Rosa-Confetti embryos. We analyzed hearts from low Dox induced Mesp1-rtTA/tetO-
Cre/Rosa-Confetti mice expressing fluorescently labelled patches at E12.5 and assessed the 
fate of the Mesp1 labelled cells on serial sections in a given unicolour patch (Fig. 4a-i). 
Surprisingly, all Mesp1 derived clones found in the LV and in the atria were unipotent, and 
differentiated into either CMs or ECs (Fig. 4c-g). The unipotent Mesp1 derived CM 
progenitors are likely to give rise to the recently identified HCN4+-unipotent FHF CM 
progenitors that are identified later during cardiac development 28, 29. While the clones of CMs 
in the ventricles remain relatively cohesive, the clones of ECs composing the endocardium 
were not cohesive and were intermingled with many unlabelled ECs (Supplementary Fig. S5). 
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In contrast, while some of the Mesp1 progenitors of the SHF were also unipotent, 
differentiating into either CM or ECs, as previously reported during avian heart development 
30, Mesp1 progenitors of the SHF can also be bipotent, especially in the outflow or inflow 
tract regions (85% of the bipotent clones), differentiating into CMs and ECs (Fig. 4c, h-h’), or 
CMs and SMCs (Fig. 4c, i-i’) at the clonal level.  
Finally, we assessed the developmental origin and fate of the progenitors of the 
epicardium, the envelope that surrounds the heart, and that give rise to the cardiac fibroblasts 
and smooth muscle cell of the coronary arteries 31 The developmental origin of the 
epicardium in respect to the other cardiovascular progenitors remains unclear 32-34. Our Mesp1 
clonal analysis revealed that 13 out of 37 unicolour induced hearts showed labelling in the 
epicardium (Fig. 4j-l), mostly arising following Dox administration at the earliest time of 
Mesp1 progenitor specification (Fig. 4j). Ten of the thirteen epicardium unicolour-labelled 
hearts (77%) showed only contribution to the epicardium (Fig. 4k), while 3 out of 13 hearts 
(23%) were also associated with labelled cardiomyocytes (Fig. 4l), suggesting that the 
majority of epicardial cells arise from an independent population of unipotent Mesp1 
progenitors that will give rise to the epicardium lineage, while a small fraction of Mesp1 
progenitors may be bipotent, giving rise to CMs and EPDCs.  
 
The molecular heterogeneity of Mesp1 progenitors reflects their regional and lineage 
restricted contribution.    
To gain further insights into the molecular mechanisms that control Mesp1 progenitor 
specification and lineage segregation during the early stage of cardiac mesoderm formation, 
we performed transcriptional profiling of Mesp1 expressing cells during the early and late 
stage of Mesp1 progenitors. To this end, we administrated Dox to Mesp1-rtTA/tet-O-H2B-
GFP embryos at E6.25, or E7.25, isolated Mesp1 H2B-GFP positive and negative cells by 
FACS 6 hours later, and performed microarray analysis in two independent biological 
experiments (Fig.  5a). At E6.5, Mesp1 was the 6th most upregulated probe out of 46 000 
probes, further demonstrating that our transgenic approach faithfully marked Mesp1 
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expressing cells. Interestingly, the comparison of these Mesp1 in vivo arrays with previous 
published arrays performed following Mesp1 overexpression or Mesp1-GFP positive cells 
during ESC differentiation 6, 7 (Fig. 5b) showed an important overlap between the genes 
differentially regulated in the Mesp1 GFP+ cells at E6.5 and the genes regulated by Mesp1 
gain of function in ESC or associated with Mesp1-GFP at D3 of ESC differentiation (Table 
S2). Gene Ontology analysis revealed that Mesp1 progenitors at E6.5 are statistically highly 
enriched in genes regulating embryonic patterning and regionalization, heart and blood vessel 
morphogenesis, and transcriptional regulation (Fig. 5c). These genes comprised many key 
transcriptional factors known to act upstream of Mesp1 (eg: Eomes, T) 35, 36, downstream of 
Mesp1 or co-regulated with Mesp1 and regulating EMT (eg: Snail1) or controlling 
cardiovascular development (e.g: Gata4, Gata6, Hand1, Meis2) 6, 8, 9 (Fig. 5d and Table1). 
Many genes controlling key developmental signaling pathways, controlling cardiovascular 
development and lineage segregation, such as Wnt, Notch, BMP, TGF-b, FGF pathways that 
are regulated by Mesp1 in vitro 6-8, were also preferentially expressed in Mesp1 expressing 
cells in vivo (Table 1). Also Mesp1 expressing cells preferentially expressed genes associated 
with cell polarity and migration (e.g: Fn, Cdh11, N-cadh, Wnt5a, Vangl1, Ninein) (Table 1), 
consistent with the role of Mesp1 in regulating cardiac progenitor migration 4, 37. Flk1 and 
Pdgfra, two genes encoding cell surface markers previously shown to mark Mesp1 expressing 
cardiovascular progenitors during mouse and human ESC and iPSC differentiation 6, 15, were 
also upregulated in Mesp1-GFP in vivo (Fig. 5e-i), and the same combination of cell surface 
markers (Flk1, Pdgfra and CXCR4) could be used to greatly enrich early Mesp1 progenitors 
during embryonic development in vivo (Fig. 5j).  
Comparison between Mesp1-GFP positive cells at E6.5 and E7.5 revealed that Mesp1 
progenitors share very similar expression profiles with several Mesp1 direct target genes, 
such that Gata4, Gata6, Aplnr were upregulated in Mesp1 positive cells at the early and late 
time points (Fig. 5k). Despite these similarities, early and late Mesp1 expressing present also 
important molecular differences including the differential expression of transcription factors 
and Hox related genes, previously identified in controlling pattern and regionalization in other 
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tissues 38-40, suggesting that these genes may regulate the patterning of the PS (Table 1). Mixl1 
41, Otx1 42, Evx1 43,, Lhx1 44 were preferentially expressed in the early Mesp1 cells  (Fig. 5k-l), 
while many genes known to be associated or controlling the morphogenesis of the SHF such 
as the Aldh1a2 45, RXRa 46, Foxh1 47, Hoxa1, Hoxb1, and Hoxb2 48, Smarcd3 49, FoxC1/C2 50, 
Cited1 51 were more highly expressed in Mesp1 progenitors at E7.5 (Fig. 5k and m). In 
addition, late Mesp1 progenitors also preferentially express genes controlling somitogenesis 
(eg: Notch1, Dll1, Lnfg, EphA4) (Table 1), consistent with the well known expression of 
Mesp1 and its target genes in the first somites 52. Altogether, the transcriptional profiling of 
Mesp1 progenitors during the early and late stage of Mesp1 expression identify known as well 
as novel putative markers distinguishing FHF and SHF progenitors.  
To further explore the molecular heterogeneity of Mesp1 progenitors during 
embryonic development, we performed single cell RT-PCR analysis to analyse the expression 
of several direct Mesp1 target genes, such as Snail1, Gata4, Gata6, Aplnr, Hoxb1, Myl7 and 
Foxc2 (Fig. 6a-h) on single FACS isolated Mesp1 H2B-GFP positive cells at E6.5 and E7.25 
(Fig. 6i and j and Supplementary Fig. S6). Interestingly, not all direct Mesp1 target genes are 
expressed in every Mesp1 positive cells at the same time. Snail1 is the most commonly Mesp1 
co-expressed gene irrespective of the embryonic stages (n=75), followed by Gata6, Gata4 
and Aplnr (Fig. 6i and j). Interestingly, at E6.5, less than 10% of Mesp1 cells expressed 
Mesp1 target genes associated with SHF (Hoxb1 and Foxc2) 48, 53  (Fig. 6i). However at E7.5, 
the number of Mesp1 cells expressing SHF markers increased by 10 fold, with 20 to 30% of 
cells expressing either Hoxb1 or FoxC2 (Fig. 6j). The analysis of the expression of Myl7, a 
marker of cardiomyocytes 54, and Etv2, a transcription factor associated with endothelial and 
endocardial cell fate 55-58, revealed that at E6.5, Mesp1 cells usually expressed either Myl7 or 
Etv2, while at latter stages more Mesp1 expressing cells co-expressed these 2 markers (Fig. 
6j), consistent with the early unipotent FHF and the late bipotent SHF progenitors found in 
our clonal analysis. These single cell transcriptional profiling of Mesp1 progenitors support 
the existence of molecularly distinct populations of Mesp1 progenitors, reflecting their 
different regional and lineage contribution.  
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Discussion 
In contrast to the current model of cardiovascular development and lineage 
segregation, in which Mesp1 is thought to mark the most primitive multipotent cardiovascular 
progenitors common to the FHF and SHF, our temporal clonal analysis of Mesp1 expressing 
cells provides compelling evidence that Mesp1 marks distinct classes of cardiovascular 
progenitors with restricted lineage differentiation at different time points during gastrulation 
(Fig. 7). The absence of evidence for common FHF and SHF progenitors does not exclude the 
possibility that a minor portion of the heart may be derived from common progenitors of both 
heart fields that escape our inducible Mesp1 lineage tracing approach. However, since the 
inducible lineage tracing data recapitulate the tracing of the Mesp1-Cre knock-in mice that 
marks all cardiac lineages, it seems more likely that the common progenitor for FHF and 
SHF, identified in retrospective clonal analysis 3, exists before gastrulation and the onset of 
Mesp1 expression in the epiblast cells expressing Eomes, a transcription factor that directly 
controls Mesp1 expression 35, 36 and marks both the FHF and SHF by lineage tracing 36. The 
temporal clonal analysis developed here to label a single heart progenitor during the early 
stage of gastrulation can be used in the future to decipher the number, temporal specification, 
regionalization, mode of expansion, and differentiation potential of developmental 
progenitors from other organs or tissues.  
Our prospective clonal analysis of heart development reveals that, unexpectedly, the 
vast majority of Mesp1 derived cardiovascular progenitors of the FHF are restricted to either 
CM or EC cell fates at the time of their specification. In contrast, Mesp1 derived SHF 
progenitors can be unipotent or bipotent. In addition, our study shows that epicardial 
progenitors arise at the early stage of cardiac mesoderm formation (Fig. 7). The major 
difference between the multilineage differentiation potential of cardiovascular progenitors in 
vitro 6, 13-15, 59 and their more restricted fate in vivo suggests that the ultimate fate of the 
progenitors can be regulated by the environmental cues that the different progenitors 
encounter during cardiac morphogenesis.  
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Our molecular analysis of Mesp1 progenitors at two different time points during 
embryonic development provides the first transcriptional profiling of the early cardiac 
progenitors in vivo and uncovered that the two populations of Mesp1 progenitors, although 
very similar molecularly, present also notable difference, consistent with their lineage and 
regional contribution. This analysis identified several key markers differentially expressed in 
the early and late Mesp1 progenitors, such as Mixl1, Otx1 and Evx1 that are preferentially 
expressed in the early Mesp1 cells while Aldh1a2, RXRa, Foxh1, FoxC1/C2, Hoxa1, Hoxb1, 
and Hoxb2, Smarcd3, all genes known to be expressed or controlling SHF morphogenesis 48, 
53, are preferentially expressed in the late Mesp1 progenitors. Further studies will be required 
to define which of these differentially regulated genes temporally and spatially control the 
emergence of the distinct populations of Mesp1 progenitors during gastrulation. In addition, 
single cell RT-PCR of Mesp1 direct target genes revealed that Mesp1 expressing cells are 
molecularly heterogeneous. While previous studies proposed that Mesp1 acts as a master 
regulator of cardiovascular development 6, 8, 9, our analysis demonstrates that Mesp1 only 
induces the expression of a combination of different direct target genes in different cell types. 
Understanding how this specificity is achieved will be important to instruct and/or restrict the 
fate of multipotent cardiovascular progenitors into a particular cell lineage in vivo. The 
answers to these questions will be important both to design new strategies to direct the 
differentiation of ESC and iPS derived cardiovascular progenitors specifically into pure 
population of CMs, and for improving cellular therapy in cardiac diseases 
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Figure Legends 
 
Figure 1: Mesp1-rtTA transgenic mice faithfully recapitulates Mesp1 endogenous 
expression. 
a. Macroscopic analysis of a Mesp1-Cre/Rosa-tdTomato embryo at E14.5. Scale bars: 500µm. 
b-c. Confocal analysis of Rosa-tdTomato (b) and Mesp1-Cre/Rosa-tdTomato heart sections 
(c) at E14.5 co-stained with anti-cardiac troponin T (cTnT) antibody. d-g. Confocal analysis 
of Mesp1-Cre/Rosa-tdTomato heart sections at E14.5 co-stained with epicardial (Wt1) (d), 
EC (endoglin) (e), pace-maker (Hcn4) (f) and SMC (smMHC) (g) markers. Scale bars: 20 
µm . lu: lumen, V: ventricle, A: atria, OFT, outflow tract, IFT, inflow tract. h. Scheme of the 
genetic strategy used for the characterization of the Mesp1-rtTA transgenic mice. DOX 
administration leads to the activation of the Cre recombinase between E6.25 and E7.5 in 
Mesp1-rtTA/TetO-Cre/Rosa-tdTomato but no activation of the Cre recombinase was detected 
when DOX was administrated later (E8.5). i-j. Confocal analysis of Rosa-tdTomato (i) and 
Mesp1-rtTA/tetO-Cre/Rosa-tdTomato heart sections (j) at E14.5 co-stained with anti-cardiac 
troponin T (cTnT). k-n. Confocal analysis of Mesp1-rtTA/TetO-Cre/Rosa-tdTomato heart 
sections at E14.5 co-stained with epicardial (Wt1) (k), EC (endoglin) (l), pace-maker (Hcn4) 
(m) and SMC (smMHC) (n) markers. Scale bars: 20 µm . lu: lumen, V: ventricle, OFT, 
outflow tract, SAN, sino-atrial node. o. Temporal analysis of the activation of the Mesp1-rtTA 
transgene. While absence of Dox administration did not induce GFP expression in the 
embryos, GFP positive cells could be detected only 5h after Dox injection in the primitive 
streak (PS) and nascent mesoderm. A, anterior; P, posterior. p. Temporal analysis of the 
recombination of the Rosa-tdTomato locus investigated by PCR following Dox 
administration. The Rosa-tdTomato locus was recombined as soon as 6h following Dox 
administration in Mesp1-rtTA/TetO-Cre/Rosa-tdTomato embryos at E6.25 and E7.25, 
similarly as found with Mesp1-Cre/Rosa-tdTomato embryos at the same time points. Negative 
controls including WT tail and Rosa-tdTomato tail show PCR amplification corresponding to 
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the unrecombined  Rosa-tdTomato locus (around 1,000bp) and Mesp1-Cre/Rosa-tdTomato 
heart at E12.5 (positive control) show recombined Rosa-tdTomato locus (about 180bp). 
 
Figure 2: Two temporally distinct populations of Mesp1 progenitors contribute to the 
FHF and SHF development. 
a. Scheme of the genetic strategy used for the clonal tracing of Mesp1 expressing progenitors 
with different fluorescent proteins to assess their regional contribution. b. Low dose of 
doxycycline (DOX) was injected between E6.25 and E7.25. Induced Mesp1-rtTA/tetO-
Cre/Rosa-Confetti unicolour embryos were analyzed at E8.5 and E12.5. c. Proportion of the 
fluorescent proteins in unicolour-labelled hearts. (n=7 unicolour hearts at E8.5 and n=37 
unicolour hearts at E12.5). d-e. Examples of Mesp1-rtTA/tetO-Cre/Rosa-Confetti unicolour 
labelled hearts at E8.5. f-g. Examples of Mesp1-rtTA/TetO-Cre/Rosa-Confetti unicolour 
labelled hearts at E12.5. Note that each patch is localized within either the FHF or the SHF 
but no unicolour patches that encompassed derivatives of the FHF and the SHF were 
observed. OFT, outflow tract; RV, right ventricle; LV, left ventricle; RA, right atrium; LA, 
left atrium; IFT, inflow tract. Scale bars: 200 µm. h-j. Examples of E12.5 unicolour hearts 
induced at E6.25 (H) and E6.75 (I) showing the labelling of FHF derived progenitors, while 
Dox administration at E7.25 shows preferential labelling of SHF progenitors (J). Scale bars: 
200 µm. k. Graph depicting in all unicolour hearts the regional contribution of the labelled 
cells and the number of clusters of labelled cells per chamber according to the developmental 
time of Dox administration. * asterisks indicates that labelling was also detected in the 
epicardial layer. l. Quantification of the regional (FHF and SHF) contribution of patches of 
Mesp1 labelled cells in unicolour hearts shows the preferential labelling of the FHF (red) 
during Dox administration at the early time points (E6.25 and E6.75), while Dox 
administration in the late stage of cardiac progenitor specification (E7.25) shows the 
preferential labelling of Mesp1 progenitors that contribute to the SHF (green) derivatives. The 
number on the upper right in each panel refers to the ID of the labelled heart. 
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Figure 3: Bio-statistical modeling of the the multicolour labelled hearts. 
a. Scheme of the genetic strategy used for the clonal tracing of Mesp1 expressing progenitors 
with different fluorescent proteins b. Low dose of doxycycline (DOX) was injected at E6.25, 
E6.75 or E7.25. Multicolour induced hearts were analyzed at E12.5 and classified according 
to their regional contribution. c. Upon Dox administration, Mesp1 expressing cells are 
stochastically labelled in different colours. During early development, cells migrate and are 
rearranged such that growing clones may fragment into disconnected clusters. d. Statistical 
analysis of uni- and multicolour hearts was performed to infer induction frequency (pN) and 
the fragmentation rate (f). e. The stochastic nature of the lineage labelling and fragmentation 
results in a broad distribution of fragment numbers (squares). With an induction frequency, 
pN=1.3, and the fragmentation rate, f=1.6, the statistical model (solid line) is in excellent 
agreement with the experimental data. n=263 hearts by colour. f. Statistical analysis, allows to 
restrict the analysis to fragments that are likely to be monoclonal with a known error rate of 
12% (Supplementary Fig. S5c and Theory). g-h. Examples of E12.5 multicolour hearts 
induced at E6.25 (g), or E7.25 (h). Scale bars: 200 µm. In the right corner is indicated which 
colour is considered as clonal, based on the statistical analysis. We compare the probability 𝐿(𝑚 = 1|𝑘) that 𝑘 fragments stem from a single clone (black line) with the probability 𝐿(𝑚 > 1|𝑘) that these fragments stem from more than one cell (solid blue line). The latter is 
given by the sum contributions of clones with multiple cell origin (dashed blue lines). We 
consider 𝑘 fragments as monoclonal, if 𝐿 𝑚 = 1 𝑘 > 𝐿(𝑚 > 1|𝑘), which leaves us with a 
threshold value of 𝑘 = 3 (dashed grey line). The circles denote fragment numbers of the three 
fluorescent markers in examples shown. i. Regional contribution of FHF and SHF progenitors 
in monoclonal datasets (n=89), showing the contribution of the FHF and SHF progenitors to 
other cardiac regions. j. Temporal appearance of FHF and SHF progenitors inferred from all 
datasets at each induction time (n=263 hearts by colour). The number on the bottom right in 
each panel refers to the ID of the labelled heart. Error bars indicate one sigma Poisson 
confidence intervals. 
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Figure 4: Clonal analysis of lineage differentiation of Mesp1 derived progenitors in vivo. 
a. Scheme of the genetic strategy used for the clonal tracing of Mesp1 expressing progenitors 
with different fluorescent proteins to assess their fate.  b. Low dose of doxycycline (DOX) 
was injected to the pregnant female between E6.25 and E7.25 and induced Mesp1-rtTA/tetO-
Cre/Rosa-Confetti embryos were analyzed at E12.5 for the expression of markers specific of 
the different cardiovascular lineages of the heart: CMs (cTnT), ECs (Endoglin) and SMCs 
(smMHC). c. Fate of the labelled cells in the different sectioned hearts is assessed by confocal 
analysis of co-immunostaining of the three markers in a given cluster. The localization of the 
patches within the different heart chambers and their FHF and SHF origin are indicated 
below. OFT, outflow tract; RV, right ventricle; LV, left ventricle; RA, right atrium; LA, left 
atrium. d-i. Confocal analysis of serial sections of fluorescently labelled hearts co-stained for 
CM and EC markers show that clones in the LV differentiated only into either CM (d) or EC 
fate (f), and no FHF progenitors show clones positive for CM and EC markers. h-i. In 
contrast, bipotent clones presenting the ability to differentiate at the clonal level into either 
CMs (h) and ECs (h’) or CMs (i) and SMCs (i’) can be observed in the SHF. Arrowheads 
point to double marked cells. Scale bars: 20 µm.  j. Percentage of labelling in the epicardium 
in unicolour hearts depending on the time of induction. k-l. Examples of E12.5 unicolour 
hearts showing labelling in the epicardial layer only (k) or in the epicardium and myocardium 
(l). Scale bars: 200 µm. The number on the upper right in each panel refers to the ID of the 
labelled heart. 
 
Figure 5: Molecular signature of early and late Mesp1 expressing cells in vivo. 
a. Genetic and cell-sorting strategy used to assess the molecular signature of early and late 
Mesp1 expressing cells in vivo. Induced Mesp1-rtTA/TetO-H2B-GFP embryos at E6.25 or 
E7.25 were dissected 6h after Dox administration. GFP positive (GFP+) and negative (GFP-) 
cells were isolated by FACS and microarrays analyses were performed in two independent 
biological experiments. b. GSEA of Mesp1-GFP signature at E6.5 showing the distribution of 
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genes upregulated by Mesp1 overexpression in ESC 6 (left) or the genes upregulated in ES 
Mesp1-GFP 7 (right). Genes are shown within the rank order list of all the microarray probe 
sets of E6.5 GFP+ cells. The highly significant enrichment score (ES) and normalized 
enrichment score (NES) are shown for each analysis. c. Gene ontology enrichment in Mesp1-
GFP expressing cells at E6.5 (black) or E7.5 (grey). d. Expression of early mesodermal 
markers, Mesp1, EMT markers such as Snai1 and cardiac progenitor markers in E6.5 Mesp1 
GFP+ cells as measured by microarrays. The fold change is presented over the GFP- 
population in duplicate samples. e. Surface marker expression in E6.5 Mesp1 GFP+ cells as 
measured by microarrays. f-i. FACs analysis showing GFP expression in E6.75 Mesp1-
rtTA/TetO-H2B-GFP embryos 6 hours following Dox administration (f). FACs analysis of the 
combined expression of Cxcr4 (blue), Pdgfra and Flk1 expression in the all living cells (g), in 
GFP- (h) and Mesp1 GFP+ (i) populations, shows that the GFP+ population is enriched in 
triple positive (TP) cells. The percentage of cells in each quadrant is shown and the 
percentage of Pdgfra+/Flk1+/ Cxcr4+ cells is shown in brackets. j. FACs analysis of E6.75 
Mesp1-rtTA/TetO-H2B-GFP embryonic cells showing that the Flk1+/Pdgfra+ double positive 
(DP) cells (red) and Flk1+/Pdgfra+/Cxcr4+ (TP) triple positive cells (blue) are highly 
enriched in Mesp1-GFP expressing cells. k. Comparison od Mesp1 expressing cells at E6.5 
and E7.5. Dot plot representing the signal of each probe (merge of the two duplicates) 
showing that some key developmental genes are differentially expressed between E6.5 and 
E7.5. l-m. mRNAs expression at E6.5 and E7.5, as defined by microarray analysis. Genes 
upregulated at E6.5 (l) and at E7.5 (m).  
 
Figure 6: Different temporal expression of Mesp1 direct target genes 
a. qRT-PCR analysis of Mesp1 target genes 24h after Dox administration in Dox inducible 
Mesp1 expression cells at D2 of ESC differentiation. The fold change is presented over the 
unstimulated cells (n=2 duplicates). b-h. Mesp1-Chip-Seq for Snai1 (b), Gata6 (c), Gata4 (d), 
Aplnr (e), Myl7 (f), Hoxb1 (g) and Foxc2 (h), showing that these genes are direct target genes 
of Mesp1 in ES cells. Red bars indicate significant peaks. i-j. Single cell RT-PCR analysis of 
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Snai1, Gata6, Gata4, Aplnr, Myl7, Hoxb1 and Foxc2 as well as Etv2 in Mesp1 GFP+ cells at 
E6.5 (i) and E7.25 (j). β-actin and Mesp1 were used as internal positive controls. A dark 
colour indicates strong expression while a light colour indicates a weak expression 
(Supplementary Fig. S6). Blank cells indicate that no PCR amplification of the genes was 
detected. Percentages of cells expressing the markers are indicated on the right.  
 
Figure 7. Revised model of the early step of cardiovascular progenitor specification and 
lineage commitment during mouse development. 
Clonal and molecular analysis of Mesp1 progenitors shows the existence of temporally 
distinct Mesp1 progenitors that contribute to the heart development. Mesp1 progenitors first 
gives rise to the FHF (in red) and then to the SHF (in green) progenitors with an overlapping 
expression of Mesp1 in the two populations at E6.75. FHF progenitors are unipotent and give 
rise to either CMs or ECs. SHF progenitors are either unipotent or bipotent. Epicardial and 
epicardial derived cells (EPDCs) arises as an independent Mesp1 derived lineage at the early 
time points.   
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Table 1 : Up-regulated genes in Mesp1 GFP+ cells in vivo 
 
Category Up-regulated genes 
1. 
Transcription 
Factors/ 
Chromatin 
Remodelling 
 
Mixl1 (23 ;3),  Meis2 (17 ;2), Mesp1 (15 ;2), Gata6 (12 ;2), Sp5 (11 ;2), Lhx1 (10 ;2), 
Hoxb1 (10 ;1.3), Snai1 (9 ;1.5), Peg3 (9 ;1.1), Klhl6 (9;3), T (8 ;1.4), Mesp2 (7 ;3), Gata4 
(7 ;2), Tbx3 (7 ;0.8), Tbx6 (6 ;2), Nfatc1 (6 ;0.6), Pdlim5 (6 ;2), Irx5 (5 ;1.2), Evx1 (5 ;1.1), 
Sall3 (5 ;1.4), Otx1 (5 ;1.0), Zfx (5 ;0.3), Odz4 (5 ;2), Whsc1l1 (4 ;0.9), Six2 (4 ;2), Cdx1 
(4 ;0.7), Id1 (3 ;0.4), Hand1 (3 ;0.6), Gabpa (3 ;1.4), Zfp423 (3 ;0.7), Msgn1 (3 ;0.8), Rreb1 
(3 ;1.0), Pbx1 (3 ;1.5), Nfat5 (3 ;1.3), Psmd9 (3 ;1.1), Foxc1 (3 ;2), Rxrg (3 ;2), Eomes (3 ;2), 
Lef1 (3 ;1.4), Zeb2 (3 ;1.3), Phc2 (3 ;1.4), Glis1 (3 ;1.3), Irx3 (2 ;0.5), Hey1 (2 ;0.8), Etv2 
(2 ;0.7), Hmga2 (2 ;0.9), Hdac2 (2 ;1.1), Sfpq (2 ;1.1), Ring1 (2 ;0.8), Zfp516 (2 ;1.5), 
Zbtb44 (2 ;0.6), Tcf4 (2 ;1.0), Nfil3 (2 ;1.3), Setdb1 (2 ;0.9), Chd7 (2 ;1.5), Terf2 (2 ;1.1), 
Eny2 (2 ;1.0), Pdlim4 (2 ;1.4), Cux1 (2 ;1.2), Klf9 (2 ;0.7), Arid3b (2 ;1.3), Cited2 (2 ;1.0), 
Wwtr1 (2 ;1.3), Kdm6b (2 ;2), Srf (2 ;2), Med13l (2 ;2), Pitx2 (2 ;2), Msx1 (2 ;2), Maml2 
(2 ;2), Msx2 (2 ;2), Rbbp8 (2 ;2), Zic3 (2 ;2), Runx1t1 (1.0 ;2), Trps1 (1.3 ;2), Smarca2 
(1.1 ;2), Plag1 (1.3 ;2), Tmpo (1.1 ;2), Tcf15 (1.1 ;2), Zfhx3 (0.5;2), Mll3 (1.3;2), Prrx2 
(1.1;2), Trp53 (1.1;2), Xab2 (1.1 ;2), Csrnp2 (1.0 ;2), Plagl2 (0.9;2), Hoxb3 (0.9;2), Med1 
(1.1 ;2), Men1 (0.6;2), Usf1 (1.0 ;2), Aff1 (0.7;2), Gfra2 (1.1 ;3), Rxra (1.0;3), Klf12 (0.6;3), 
Nasp (1.4;3), Runx2 (1.2 ;3), Meox1 (1.0 ;4) 
2. Signaling  
Notch Dll3 (14 ;2), Aph1b//Aph1c (6 ;2), Dlk1 (3 ;0.6), Jag1 (3 ;2), Hey1 (2 ;0.8), Notch1 (2 ;2), Maml2 (2 ;2), Dll1 (2 ;3), Lfng (2 ;3), Sel1l (1.0 ;2), Numb (0.8;2), 
Wnt 
Frzb (22 ;3), Wnt5a (9 ;2), Wnt3 (5 ;2), Wnt2b (4 ;2), Dact1 (4 ;2), Wls (3 ;1.1), Lef1 
(3 ;1.4), Fzd1 (3;1.1), Wnt2 (3;2), Axin2 (3 ;1.1), Lrrfip2 (2;2), Ctnnbip1 (2 ;1.2), Wnt5b 
(2 ;0.9), Rspo3 (2;1.0), Tcf4 (2 ;1.0), Apcdd1 (1.7 ;0.9) 
TGF-β Lefty2 (5 ;2), Tgfb1 (5 ;1.2), Dcp1a (2;1.2), Fstl1 (3 ;1.0), 
FGF Fgf3 (11 ;1.2), Fgf10 (5 ;0.7), Fgf4 (3 ;2), Fgfrl1 (2 ;1.0), Spred1 (6 ;1.3) 
BMP Bmp7 (7 ;1.0), Smad1 (6 ;2),  Bmper (3 ;1.2), Fst (3 ;2), Tdgf1 (3 ;5), Smad5 (2 ;1.0), Usp9x (2;0.9), Egr1 (2;1.1), Cer1 (0.3;2), Twsg1 (1.2;2) 
Retinoic acid Cyp26a1 (7; 1), Rarb (1;2), Rarg (2. 2), Rxra (2.2), Rxrg (3; 2), 
Others 
Aplnr (34;2), Dlc1 (12 ;2), Gas1 (10 ;1.4), Gna14 (9 ;1.3), Klhl6 (9 ;3), Prkd1 (7 ;2),  
Rasgrp3 (4 ;2), Rftn1 (4 ;1.4) ; Apln (3 ;0.9), Gpr50 (3 ;1.0), Braf (3 ;1.0), Igfbp4 (3 ;2), 
Ptch1 (3 ;2),  Neo1 (3 ;4), Gna13 (2 ;1.0), Peli1 (2 ;1.3), Flt1 (2 ;1.3), Ppp2ca (2 ;2), Dusp9 
(2 ;2), Srgap3 (1.7 ;1.1), Pcsk5 (1.3;2), Igsf10 (0.6;2), Arfrp1 (1.3;2), Rnf111 (1.2;2), Ptpra 
(1.3;3), Dab2 (0.4 ;3), Egfr (1.0 ;3), Litaf (2;1.0), Gnai1 (2;1.0),  S1pr5 (3;1.2), Adcyap1r1 
(4;2),  Adra2b (2;2), Adora2b (2;1.3), Ptpn1 (2;2), Col4a3bp (2;1.1), Gjc1 (2;1.4), Tiparp 
(3;1.0), Nck1 (2;1.3), Arl4d (3;1.2), Hrasls (2;0.9), Rabl3 (2;1.2), Rab8b (7;2), Ralgps2 
(2;1.2), Wsb1 (2;2), Asb4 (4;0.6), Lrrk1 (2;1.0), Map3k3 (2;1.2), Pth1r (2;2), Arf1 (4;0.6), 
Rhot1 (2;1.0), Tlk1 (2;0.9), Rala (2;0.6), Dab1 (2;0.9), Yaf2 (2;1.0), Rbm14 (2;0.9), Atl1 
(3;1.1), Lpar6 (1.8 ;1.2) 
3. Migration/ 
Polarity / 
Guidance 
Fn1 (18 ;3), Cdh11 (12 ;1.3), Pcdh7 (11 ;2), Adam19 (12 ;3), Pdgfra (9 ;1.4), Epha4 
(8 ;1.2), Nin (8 ;2), Cxcr4 (8 ;2), Flk1 (7 ;1.2), Cdh2/Ncad (6 ;1.2), L1cam (6 ;2), Mmp14 
(5 ;1.1), Cdh4 (5 ;1.3), Vangl1 (5 ;0.9), Prtg (5 ;1.4), Pcdh8 (5 ;4), Cdc42ep4 (4 ;0.8), Efna3 
(4 ;1.2), Sema5a (4 ;0.8), Slit3 (4 ;1.3),Vcan (4 ;0.9), Dock11 (4 ;2), Itga5 (4 ;2), Mfap4 
(3 ;1.8), Fat3 (3 ;1.5), Agtrap (3;1.0), Pcdh18 (3 ;1.2), Nrp2 (3 ;1.0),  Pafah1b1 (3;0.6), 
Efnb3 (3;0.9), Enah (3 ;3), Plxna2 (3 ;3), Lin7c (3;3), Timp3 (2;2), Robo1 (2 ;1.2), Anks1 
(2 ;0.9), Adam10 (2 ;0.6), Adamts9 (2 ;0.8), Hipk2 (2 ;1.0), Gpc3 (2 ;1.8), Efna1 (2 ;0.8), 
Has2 (2 ;0.6), Ngfr (2;1.0), Dpysl5 (2;1.0), Afg3l2 (2;1.3), Epha1 (2;1.4), Adra2b (2 ;2), 
Pdgfrb (2 ;2), Fbn2 (2;2), Col27a1 (3;2), Gad1 (2;1.1), Gls (2;1.3),  Itgb1 (2;1.4), Ilk (2;1.1), 
Evl (2;1.0), Cyfip1 (2;1.2), Pcdh19 (2 ;3), Efnb1 (1.3 ;2), Prickle1 (1.4;2), Itga8 (1.4 ;2), 
Ryk (0.8;2), Rgnef (0.3 ;2), Itgav (3;1.1), 
4. Others 
Ifitm1 (8 ;1.4), Ptprj (6 ;1.2), Rnd3 (6 ;1.0), Chst2 (6 ;2), Man1c1 (6 ;2), Cbln1 (6 ;3), . 
Anpep (6 ;3), Ccnd2 (5 ;0.8), Usp3 (5 ;1.4), Rimbp2 (5 ;2), Dclk1 (5 ;3), Cachd1 (4 ;1.4), 
Vldlr (4 ;1.2), Birc6 (4;0.8), Wwp1 (4;0.6),  Atp11c (3 ;0.4), Phlda2 (3 ;1.0), Chst7 (3 ;1.1), 
Atg5 (3;1.5), Ppic (3 ;1.0), Hs3st3b1 (3 ;0.9), Cask (3;1.4), Wars2 (3;1.3), Man1a2 (3;1.1), 
Chek1 (2 ;0.4), Grsf1 (2 ;0.6), Olfm1 (2 ;1.1), Alox15 (2 ;1.1), Cdkn1c (2 ;1.3), Pmp22 
(2 ;0.8), Leprel1 (2 ;0.9), Stxbp5 (2 ;1.4), Tes (2 ;1.1), Galnt7 (2 ;1.0), Slc11a2 (2;1.1), 
Ipmk (2;1.1), Egln3 (2 ;1.5), Phldb2 (2 ;2), Laptm4b (2 ;2), Kif3a (2 ;2), Trim72 (2 ;2), 
Sbsn (2 ;3), Flnb (1.3 ;2), Bace2 (1.9 ;3), Slc38a5 (1.6 ;1.1), Grrp1 (1.7 ;0.9), Vamp4 
(1.7 ;1.7), Snta1 (1.3 ;2), Gys1 (0.7 ;3), Txnrd2 (1.0 ;3), Actc1 (1.1 ;3), Tnnc1 (0.8;10), 
 
Description of genes displaying a change in expression of >2 fold between Mesp1-GFP+ and 
Mesp1-GFP- cells at E6.5 and 7.5. (Fold change over GFP- cells at E6.5 ; Fold change over 
GFP- cells at E7.5) in 2 independent biological replicates. A gene ontology analysis was used 
to classify  the up-regulated genes in the following categories : Transcription 
Factors/Chromatin Remodelling, Signaling pathways, Migration/Polarity/Guidance and 
Others (all biological function related to early embryo development that we can not put in any 
previous classes). In bold (overexpressed in Mesp1 GOF ESC) Underlined (overexpressed in 
Mesp1-GFP ESC). 
 
